NO20060772L - Formulering for et proteinlegemiddel uten tilsatt serum albumin (HSA) - Google Patents
Formulering for et proteinlegemiddel uten tilsatt serum albumin (HSA)Info
- Publication number
- NO20060772L NO20060772L NO20060772A NO20060772A NO20060772L NO 20060772 L NO20060772 L NO 20060772L NO 20060772 A NO20060772 A NO 20060772A NO 20060772 A NO20060772 A NO 20060772A NO 20060772 L NO20060772 L NO 20060772L
- Authority
- NO
- Norway
- Prior art keywords
- hsa
- formulation
- serum albumin
- protein drug
- added serum
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det beskrives et preparat for stabilisering av proteinmidler i farmasøytika, der preparatet omfatter de følgende to bestanddeler: a) en overflateaktiv substans, fortrinnsvis en ikke-ionisk detergens (tensid), og b) en blanding av minst to aminosyrer, der de minst to aminosyrer er enten Glu og Gln eller Asp og Asn.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10333317A DE10333317A1 (de) | 2003-07-22 | 2003-07-22 | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
PCT/DE2004/001635 WO2005007185A2 (de) | 2003-07-22 | 2004-07-22 | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060772L true NO20060772L (no) | 2006-04-19 |
Family
ID=34071833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060772A NO20060772L (no) | 2003-07-22 | 2006-02-17 | Formulering for et proteinlegemiddel uten tilsatt serum albumin (HSA) |
Country Status (15)
Country | Link |
---|---|
US (1) | US7829525B2 (no) |
EP (1) | EP1648485B2 (no) |
JP (1) | JP4912147B2 (no) |
KR (1) | KR101176579B1 (no) |
CN (1) | CN100450542C (no) |
AT (1) | ATE506071T1 (no) |
AU (1) | AU2004257391B2 (no) |
BR (1) | BRPI0412241A (no) |
CA (1) | CA2532475C (no) |
DE (2) | DE10333317A1 (no) |
ES (1) | ES2363600T5 (no) |
IL (1) | IL172835A (no) |
NO (1) | NO20060772L (no) |
RU (2) | RU2491927C2 (no) |
WO (1) | WO2005007185A2 (no) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US8974774B2 (en) | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
ZA200707352B (en) | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
DE102005025520A1 (de) | 2005-06-03 | 2006-12-07 | Robert Bosch Gmbh | Verfahren zur modellbasierten Diagnose eines mechatronischen Systems |
JP5033798B2 (ja) * | 2005-07-02 | 2012-09-26 | アレコー・リミテッド | タンパク質を含む安定水系 |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
AU2016204034B2 (en) * | 2005-10-06 | 2017-12-21 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
AU2013202329B2 (en) * | 2005-10-06 | 2016-04-14 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
KR101087017B1 (ko) * | 2007-07-10 | 2011-12-09 | (주)메디톡스 | 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물 |
SI2198007T1 (en) | 2007-09-14 | 2018-04-30 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing Clostridium difficile A and B toxoids |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
CN102066401A (zh) | 2008-05-01 | 2011-05-18 | 艾瑞克有限公司 | 蛋白质制品 |
KR102005930B1 (ko) | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
BRPI1015938A2 (pt) | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
ES2693705T3 (es) | 2009-07-02 | 2018-12-13 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxinas que muestran actividad biológica reducida |
KR20120120141A (ko) * | 2009-10-30 | 2012-11-01 | 듀오젝트 메디컬 시스템즈, 아이엔씨. | 치료 또는 미용 조성물의 국소 투여를 위한 장치 및 방법 |
SI3295957T1 (sl) | 2010-01-15 | 2020-02-28 | Kirin-Amgen, Inc. | Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice |
CN102408467B (zh) * | 2010-09-26 | 2014-03-05 | 海口维瑅瑷生物研究院 | 真空干燥蛋白的方法、制得的蛋白产品和试剂盒 |
CA2814054A1 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
RU2574011C2 (ru) * | 2011-03-31 | 2016-01-27 | Меди-Токс Инк. | Лиофилизированный препарат ботулотоксина |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
CA2777431A1 (en) | 2011-05-20 | 2012-11-20 | Nitto Denko Corporation | Pharmaceutical composition and method for producing the same |
US9321848B2 (en) | 2011-06-28 | 2016-04-26 | Leukocare Ag | Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide |
CN104023743B (zh) | 2011-10-25 | 2017-05-03 | 普罗西纳治疗有限公司 | 抗体制剂和方法 |
JP6162135B2 (ja) | 2011-11-09 | 2017-07-12 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 短縮された生物活性を示す神経毒 |
CN102441172B (zh) * | 2011-12-06 | 2014-05-07 | 中国医学科学院输血研究所 | 高纯度凝血酶原复合物制品冷冻干燥稳定剂 |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
LT3014267T (lt) | 2013-06-28 | 2018-12-10 | Merz Pharma Gmbh & Co. Kgaa | Priemonės ir būdai, skirti neurotoksinių polipeptidų nustatymui |
US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
US10900955B2 (en) | 2014-12-19 | 2021-01-26 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of BoNT/E in cells |
ES2788999T3 (es) * | 2014-12-23 | 2020-10-23 | Merz Pharma Gmbh & Co Kgaa | Envase prellenado de toxina botulínica |
EP3253364A1 (en) * | 2015-02-03 | 2017-12-13 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin prefilled container |
MX2018008855A (es) | 2016-03-02 | 2018-11-29 | Merz Pharma Gmbh & Co Kgaa | Composicion que comprende toxina botulinica. |
SI3463432T1 (sl) | 2016-05-27 | 2021-02-26 | Ipsen Biopharm Limited | Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom |
WO2018038585A1 (ko) * | 2016-08-26 | 2018-03-01 | 주식회사 에이비바이오 | 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법 |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
EP3290437A1 (en) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Novel recombinant clostridial neurotoxins with decreased duration of effect |
CN109803672A (zh) * | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 稳定的非蛋白质梭菌毒素组合物 |
WO2018050874A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method of producing a liquid biopharmaceutical drug product |
RU2744630C2 (ru) | 2016-09-16 | 2021-03-12 | Льюкокэар Аг | Новый способ стабилизации биофармацевтического лекарственного продукта при производстве |
US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
EP3312193A1 (en) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with accelerated onset of effect |
EP3333179A1 (en) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with accelarated onset of effect |
EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
KR20190126794A (ko) | 2017-03-24 | 2019-11-12 | 메르츠 파마 게엠베하 운트 코. 카가아 | 타액과다증의 치료에서의 보툴리늄 신경독소의 개선된 용도 |
WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
EP3642222A1 (en) | 2017-06-20 | 2020-04-29 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
US20210008156A1 (en) | 2017-10-26 | 2021-01-14 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum neurotoxins with increased duration of effect |
US20200354706A1 (en) | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
KR102063475B1 (ko) * | 2018-02-22 | 2020-01-09 | 주식회사 에이비바이오 | 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법 |
US20210393748A1 (en) | 2018-10-02 | 2021-12-23 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for treating lipoedema |
WO2020111852A1 (ko) | 2018-11-30 | 2020-06-04 | 주식회사 휴온스글로벌 | 보툴리눔 독소의 안정화 액상 조성물 |
KR102259423B1 (ko) | 2018-11-30 | 2021-06-02 | 주식회사 휴온스바이오파마 | 보툴리눔 독소의 안정화 액상 조성물 |
CN109602705A (zh) * | 2018-12-26 | 2019-04-12 | 安徽安科生物工程(集团)股份有限公司 | 一种重组人干扰素α2b喷雾剂 |
CN113573727A (zh) | 2019-02-21 | 2021-10-29 | 梅尔兹制药公司 | 肉毒神经毒素用于治疗震颤的新用途 |
WO2021152121A1 (en) | 2020-01-30 | 2021-08-05 | Leukocare Ag | Reduction of adsorption |
JP2023529095A (ja) | 2020-06-05 | 2023-07-07 | メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー | 高用量低体積のボツリヌス毒素による顔のシワの治療 |
CN112168789B (zh) * | 2020-09-25 | 2022-08-16 | 广州一品红制药有限公司 | 一种包含氨基酸的注射用乙酰谷酰胺药物组合物及其应用 |
CN114642729B (zh) * | 2020-12-21 | 2023-12-15 | 舒泰神(北京)生物制药股份有限公司 | 一种凝血因子x激活剂组合物 |
TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及/或皮脂產生之用途、以及降低皮膚毛孔尺寸及/或皮脂產生的方法 |
WO2024115413A1 (en) | 2022-11-28 | 2024-06-06 | Merz Pharma Gmbh & Co. Kgaa | High concentration botulinum toxin treatment for neck rejuvenation |
WO2024115412A1 (en) | 2022-11-28 | 2024-06-06 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin injection in platysma for lower face and neck rejuvenation |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3033932C2 (de) * | 1980-09-10 | 1984-05-24 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten |
US4895716A (en) * | 1987-06-09 | 1990-01-23 | Biogen, Inc. | Stabilized formulations of gamma interferons |
JPH01246226A (ja) * | 1988-03-28 | 1989-10-02 | Sumitomo Pharmaceut Co Ltd | 安定な修飾アスパラギナーゼ含有組成物 |
IE64738B1 (en) * | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
DE4111393A1 (de) † | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
DK204791D0 (da) | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
US5762993A (en) * | 1992-02-19 | 1998-06-09 | Kraft Foods, Inc. | Process for preparing reduced fat meat |
JP2886061B2 (ja) * | 1993-10-29 | 1999-04-26 | 財団法人化学及血清療法研究所 | プロテインcもしくは活性化プロテインcの安定化方法及び安定化組成物 |
FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
DE19508192A1 (de) * | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
DK0837883T3 (da) * | 1995-06-07 | 2005-12-19 | Chiron Corp | Fremgangsmåde til oplösning, oprensning og genfoldning af protein |
TW497972B (en) * | 1995-06-08 | 2002-08-11 | Kirin Brewery | Stable thrombopoietin (TPO)-containing lyophilized compositions |
ATE255903T1 (de) * | 1995-11-07 | 2003-12-15 | Genentech Inc | Stabilisierende formulierung für ngf |
US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
TWI240627B (en) * | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
WO1999055310A1 (en) * | 1998-04-27 | 1999-11-04 | Altus Biologics Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
JP2000072873A (ja) * | 1998-06-18 | 2000-03-07 | Kao Corp | 含窒素高分子化合物 |
US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
RU2244556C2 (ru) * | 1999-02-22 | 2005-01-20 | Юниверсити Оф Коннектикут | Новые не содержащие альбумин составы фактора viii |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
NZ515380A (en) * | 1999-04-09 | 2003-10-31 | Ortho Mcneil Pharm Inc | Aqueous stable preserved pharmaceutical compositions of erythropoietin |
US6465425B1 (en) * | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US20050013867A1 (en) * | 2001-10-19 | 2005-01-20 | Lehrman S. Russ | Use of proton sequestering agents in drug formulations |
US7005144B2 (en) * | 2002-06-07 | 2006-02-28 | Eve Szu-Ju Chen | Antler composition and its manufacturing process |
-
2003
- 2003-07-22 DE DE10333317A patent/DE10333317A1/de not_active Withdrawn
-
2004
- 2004-07-22 KR KR1020067001593A patent/KR101176579B1/ko not_active IP Right Cessation
- 2004-07-22 DE DE502004012418T patent/DE502004012418D1/de not_active Expired - Lifetime
- 2004-07-22 RU RU2008147818/15A patent/RU2491927C2/ru not_active IP Right Cessation
- 2004-07-22 BR BRPI0412241-0A patent/BRPI0412241A/pt not_active IP Right Cessation
- 2004-07-22 ES ES04762485.3T patent/ES2363600T5/es not_active Expired - Lifetime
- 2004-07-22 JP JP2006520664A patent/JP4912147B2/ja not_active Expired - Fee Related
- 2004-07-22 CN CNB2004800211416A patent/CN100450542C/zh not_active Expired - Fee Related
- 2004-07-22 AT AT04762485T patent/ATE506071T1/de active
- 2004-07-22 RU RU2006101589/15A patent/RU2354366C2/ru not_active IP Right Cessation
- 2004-07-22 EP EP04762485.3A patent/EP1648485B2/de not_active Expired - Lifetime
- 2004-07-22 AU AU2004257391A patent/AU2004257391B2/en not_active Ceased
- 2004-07-22 CA CA2532475A patent/CA2532475C/en not_active Expired - Fee Related
- 2004-07-22 US US10/565,111 patent/US7829525B2/en not_active Expired - Fee Related
- 2004-07-22 WO PCT/DE2004/001635 patent/WO2005007185A2/de active Application Filing
-
2005
- 2005-12-26 IL IL172835A patent/IL172835A/en not_active IP Right Cessation
-
2006
- 2006-02-17 NO NO20060772A patent/NO20060772L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE10333317A1 (de) | 2005-02-17 |
ATE506071T1 (de) | 2011-05-15 |
CN100450542C (zh) | 2009-01-14 |
WO2005007185A2 (de) | 2005-01-27 |
RU2354366C2 (ru) | 2009-05-10 |
ES2363600T3 (es) | 2011-08-10 |
CA2532475A1 (en) | 2005-01-27 |
DE502004012418D1 (de) | 2011-06-01 |
ES2363600T5 (es) | 2014-12-05 |
EP1648485B2 (de) | 2014-09-24 |
WO2005007185A3 (de) | 2005-05-12 |
RU2491927C2 (ru) | 2013-09-10 |
JP2006528137A (ja) | 2006-12-14 |
CN1826132A (zh) | 2006-08-30 |
BRPI0412241A (pt) | 2006-10-17 |
IL172835A (en) | 2010-06-16 |
IL172835A0 (en) | 2006-06-11 |
EP1648485B1 (de) | 2011-04-20 |
AU2004257391A1 (en) | 2005-01-27 |
RU2006101589A (ru) | 2006-09-10 |
US7829525B2 (en) | 2010-11-09 |
KR101176579B1 (ko) | 2012-08-23 |
KR20060031697A (ko) | 2006-04-12 |
US20070134199A1 (en) | 2007-06-14 |
CA2532475C (en) | 2013-05-28 |
EP1648485A2 (de) | 2006-04-26 |
JP4912147B2 (ja) | 2012-04-11 |
AU2004257391B2 (en) | 2010-02-11 |
RU2008147818A (ru) | 2010-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060772L (no) | Formulering for et proteinlegemiddel uten tilsatt serum albumin (HSA) | |
Gustafson et al. | New Circulin Macrocyclic Polypeptides from Chassalia p arvifolia | |
KR100491281B1 (ko) | 저당함량을가지는안정한알부민무함유재조합인자Vlll의제제 | |
Havell et al. | Altered molecular species of human interferon produced in the presence of inhibitors of glycosylation. | |
DK1432738T3 (da) | Carbonhydratbindingsdomæne indeholdende fusionsproteiner til afgivelse af terapeutiske og andre midler samt sammensætninger indeholdende fusionsproteinerne | |
DE59504750D1 (de) | Verfahren zur gewinnung von hochreinem von willebrand-faktor | |
CY1114244T1 (el) | Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση | |
NO965012L (no) | Farmasöytisk preparat som omfatter glukagon | |
NO20070372L (no) | Amidoforbindelser og anvendelse derav som farmasoytiske preparater | |
BRPI0517924A (pt) | formas polimórficas de 6-[2(metilcarbamoil) fenilsufanil]-3-e-[2-(piridin-2-il)etenil] indazol | |
KR20010020242A (ko) | 활성화 프로틴c의 가공을 위한 개선된 방법 | |
EE200300587A (et) | Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine | |
WO2005067601A3 (en) | Vectors for recombinant protein expression in e.coli | |
Lacroix et al. | Structure and assembly of the catalytic region of human complement protease C1r: a three-dimensional model based on chemical cross-linking and homology modeling | |
EP2292255A3 (de) | Stabile therapeutische Proteine | |
DK1117661T3 (da) | Propanolaminderivater substitueret med heterocycliske grupper, fremgangsmåde til deres fremstilling, farmaceutiske præparater indeholdende disse forbindelser og deres anvendelse | |
Kelley et al. | Equilibrium and kinetic measurements of the conformational transition of reduced thioredoxin | |
Schwarzer et al. | The Na/Ca-K exchanger of rod photoreceptor exists as dimer in the plasma membrane | |
GR1000637B (el) | Συνθεσεις για τοπικη χρηση που περιεχουν αποπολυμερισμενα δεοξυριβονουκλεινικα οξεα για τον καλλωπισμο του δερματος και του σωματος. | |
ATE553747T1 (de) | Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält | |
Prasad et al. | Effect of disaccharides on the stabilization of bovine trypsin against detergent and autolysis | |
Abgar et al. | Chaperone-like activity of bovine lens α-crystallin in the presence of dithiothreitol-destabilized proteins: characterization of the formed complexes | |
Sturrock et al. | Assignment of free and disulfide-bonded cysteine residues in testis angiotensin-converting enzyme: functional implications | |
Ogasahara et al. | Equilibrium and kinetic analyses of unfolding and refolding for the conserved proline mutants of tryptophan synthase α subunit | |
Beldarrain et al. | Thermal denaturation of human γ-interferon. A calorimetric and spectroscopic study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |